AbbVie 경영진
경영진 기준 점검 2/4
AbbVie CEO는 Robert Michael, Jul2024 에 임명되었습니다 의 임기는 2.17 년입니다. 총 연간 보상은 $32.53M, 5.2% 급여 및 94.8% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $45.56M 가치에 해당하는 회사 주식의 0.01% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.4 년과 8.8 년입니다.
핵심 정보
Robert Michael
최고경영자
US$32.5m
총 보수
| CEO 급여 비율 | 5.23% |
| CEO 재임 기간 | 2.2yrs |
| CEO 지분 보유율 | 0.01% |
| 경영진 평균 재임 기간 | 2.4yrs |
| 이사회 평균 재임 기간 | 8.8yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • Sep 04
AbbVie: Shares Defy Sell-Side Downgrades, And That's Bullish (Technical Analysis)
Summary AbbVie remains a 'Buy', supported by robust fundamentals, a strong immunology portfolio, and attractive valuation metrics. The recent $11B Apogee Therapeutics acquisition enhances ABBV's pipeline in immunology, oncology, neuroscience, and aesthetics, with only modest near-term EPS dilution. Q2 results beat expectations, driven by Skyrizi and Rinvoq, while technicals and momentum favor continued upside toward a $292 price target. Key risks include increased competition, clinical trial outcomes, and balance sheet monitoring; upcoming conferences and earnings may introduce near-term volatility. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 07
ABBV: Future Returns Will Hinge On Apogee Respiratory Bet
Analysts have nudged their fair value estimate for AbbVie higher to about $273 per share. This reflects refreshed models that factor in Q2 updates, stronger confidence in long term margins, and the potential impact of the Apogee acquisition, while still using a slightly higher discount rate and a modestly lower future P/E assumption.내러티브 업데이트 • Jul 24
ABBV: Future Returns Will Rely On Apogee Deal And Broader Pipeline Execution
AbbVie’s updated analyst price target has increased to $266.89 from $259.46 as analysts factor in recent Q2 preview research, higher modeled profit margins, and a slightly adjusted discount rate and future P/E outlook. Analyst Commentary Recent research commentary around AbbVie points to a broadly constructive tone ahead of Q2 results, with several firms revisiting their models, adjusting P/E assumptions, and updating margin and pipeline expectations.내러티브 업데이트 • Jul 10
ABBV: Future Returns Will Depend On Apogee Deal And Broader Immunology Expansion
AbbVie’s refreshed analyst price target framework edges higher to about $259 from roughly $254, with analysts pointing to updated Q2 models, recent target hikes across several firms, and added confidence around the Apogee acquisition’s immunology and respiratory potential as key supports for the revision. Analyst Commentary Recent research on AbbVie centers on two main themes, the refreshed Q2 earnings models and the planned Apogee Therapeutics acquisition.내러티브 업데이트 • Jun 23
ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline
Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.분석 기사 • Jun 16
AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...내러티브 업데이트 • Jun 06
ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution
AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.분석 기사 • May 15
We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...내러티브 업데이트 • Apr 23
ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.내러티브 업데이트 • Apr 08
ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.내러티브 업데이트 • Mar 24
ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.내러티브 업데이트 • Mar 10
ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.내러티브 업데이트 • Feb 22
ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.내러티브 업데이트 • Feb 07
ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.내러티브 업데이트 • Jan 24
ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.내러티브 업데이트 • Jan 09
ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.분석 기사 • Jan 08
AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$6b |
| Mar 31 2026 | n/a | n/a | US$4b |
| Dec 31 2025 | US$33m | US$2m | US$4b |
| Sep 30 2025 | n/a | n/a | US$2b |
| Jun 30 2025 | n/a | n/a | US$4b |
| Mar 31 2025 | n/a | n/a | US$4b |
| Dec 31 2024 | US$18m | US$2m | US$4b |
| Sep 30 2024 | n/a | n/a | US$5b |
| Jun 30 2024 | n/a | n/a | US$5b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$14m | US$1m | US$5b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$9b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$10m | US$1m | US$12b |
| Sep 30 2022 | n/a | n/a | US$13b |
| Jun 30 2022 | n/a | n/a | US$13b |
| Mar 31 2022 | n/a | n/a | US$12b |
| Dec 31 2021 | US$12m | US$1m | US$11b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$7b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$13m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$9m | US$907k | US$8b |
보상 대 시장: Robert의 총 보수(USD32.53M)는 US 시장에서 비슷한 규모 기업의 평균(USD14.74M)보다 높습니다.
보상과 수익: Robert의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Robert Michael (56 yo)
2.2yrs
재임 기간
US$32,530,984
보수
Mr. Robert A. Michael, C.P.A., served as Chief Operating Officer at AbbVie Inc. since June 29, 2023 until July 01, 2024 and served as its President since June 23, 2022 until July 01, 2024 also serves as it...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2.2yrs | US$32.53m | 0.010% $ 45.6m | |
| Executive VP & CFO | 4.3yrs | US$12.35m | 0.0022% $ 9.9m | |
| Executive VP & COO | 2.2yrs | US$10.79m | 0.012% $ 52.1m | |
| Executive VP of Research & Development and Chief Scientific Officer | 2.2yrs | US$9.91m | 0.0031% $ 14.1m | |
| Executive VP & Chief Commercial Officer | no data | US$15.44m | 0.0048% $ 21.5m | |
| Senior VP & Chief Information Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Investor Relations | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP | 3.9yrs | 데이터 없음 | 0.00026% $ 1.2m | |
| Executive VP & Chief Human Resources Officer | 1.7yrs | 데이터 없음 | 0.00045% $ 2.0m | |
| Senior VP & President of Oncology | 2.9yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP and Chief Business & Strategy Officer | 3.7yrs | 데이터 없음 | 0.0042% $ 19.0m | |
| Senior Vice President of Corporate Affairs | 2.7yrs | 데이터 없음 | 데이터 없음 |
2.4yrs
평균 재임 기간
55yo
평균 나이
경험이 풍부한 관리: ABBV의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.4 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 2.2yrs | US$32.53m | 0.010% $ 45.6m | |
| Lead Independent Director | 13.7yrs | US$432.88k | 0.00065% $ 2.9m | |
| Independent Director | 6.3yrs | US$397.88k | 0.0071% $ 31.9m | |
| Independent Director | 1.3yrs | US$328.71k | 0.00017% $ 766.0k | |
| Independent Director | 13.7yrs | US$383.44k | 0.0010% $ 4.6m | |
| Independent Director | 13.7yrs | US$382.88k | 데이터 없음 | |
| Independent Director | 13.7yrs | US$402.88k | 0.00011% $ 495.7k | |
| Independent Director | 9.3yrs | US$407.88k | 데이터 없음 | |
| Independent Director | 10.7yrs | US$397.88k | 데이터 없음 | |
| Independent Director | 8.3yrs | US$372.88k | 데이터 없음 | |
| Independent Director | 2.9yrs | US$359.51k | 데이터 없음 | |
| Independent Director | 2.9yrs | US$372.88k | 데이터 없음 |
8.8yrs
평균 재임 기간
67.5yo
평균 나이
경험이 풍부한 이사회: ABBV의 이사회는 경험이 있음으로 간주됩니다(평균 재임 8.8 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/11 04:05 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AbbVie Inc.는 51명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |